Alibaba AI Model Outperforms Radiologists in Detecting Early Colorectal Cancer
Coca AI achieves 86.6% sensitivity and 99.8% specificity in study of over 27,000 patients, published in Annals of Oncology
Auf einen Blick
- Alibaba's research arm Damo Academy has developed an AI model called Coca that detects early-stage colorectal cancer from CT scans with 86.6% sensitivity and 99.8% specificity.
- In tests on over 27,000 people, the model identified five previously missed cases and outperformed 10 radiologists by 20.4%, offering a non-invasive alternative to colonoscopy.
KI-generierte Zusammenfassung
Warum es wichtig ist
Alibaba is expanding its AI capabilities across various sectors. This medical AI development comes as Chinese tech companies increasingly compete in healthcare technology. Colorectal cancer is a leading cause of cancer deaths globally, with early detection critical to survival rates.
Alibaba Group Holding has released an artificial intelligence model that it claims is more sensitive than radiologists in spotting early stage colorectal cancer from computed tomography (CT) scans, as the Chinese tech giant doubles down on its efforts to develop AI tools for cancer detection. Alibaba's research arm Damo Academy said on Tuesday that its new Coca AI model accurately identified five previously missed cases of colorectal cancer from the non-contrast CT scans of more than 27,000 people, achieving a sensitivity of 86.6 per cent and a specificity of 99.8 per cent. Alibaba owns the South China Morning Post. Sensitivity measures a system's ability to correctly identify people with a disease, while specificity shows its ability to identify healthy individuals. Damo Academy said that Coca, developed with Chinese institutions including the Guangdong General Hospital, demonstrated a significantly higher sensitivity compared with 10 radiologists of varying levels of experience, outperforming them by 20.4 per cent. Current diagnostic methods for colorectal cancer detection, including colonoscopy and CT colonography, were invasive and created discomfort for patients, whereas Coca had the potential to be a non-invasive, cost-effective and scalable tool, Damo researchers said in a paper published in the Annals of Oncology peer-reviewed medical journal last week.
Worauf zu achten ist
KI-Ausblick — Möglichkeiten, keine Fakten
Alibaba will seek regulatory approval for Coca in China within the next 12-18 months
Wahrscheinlich · Innerhalb von Monaten
Alibaba may partner with more hospitals to expand training data for Coca
Wahrscheinlich · Innerhalb von Monaten
Offene Fragen
- When will Coca receive regulatory approval for clinical use?
- How will Alibaba commercialize this technology?
- What are the next steps for expanding the AI to detect other cancers?





